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ABUSE OF MONOAMINE OXIDASE INHIBITORS 
JAMBUR ANANTH, J.RANDOLPH SWARTZ, RANGASWAMY GADASALLY, 
KARL BURGOYNE 
Abuse of monoamine oxidase inhibitors is not common but there are a few cases of addiction in the 
literature. Most of these patients had an additional diagnosis, either history of past drug abuse or 
personality disorder and MAOI withdrawal symptoms have been reported. We encountered three 
patients who received MAOI under psychiatric care. They were all self medicated by increasing tlie 
doses on their own, experienced euphoria and visited various physicians to obtain MAOI prescriptions 
and manifested toxic states. One of our patients had a normal, another a schizoid and the third, an 
addictive personality. Two were addicted in the past to amplietamine. Therefore, it is important not to 
prescribe MAOI's to patients who have a history of amphetamine and other addictions. 
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INTRODUCTION 
Monoamine oxidase inhibitors (MAOI) were in-
troduced to psychiatry after Isonicotinic acid 
hydrazide, an antituberculous drug, was found to 
improve mood in patients suffering from tuber-
culosis (Selikoff, 1952). Among the many MAOI 
that were introduced to the market only two, phenel-
zine and tranylcypromine, have been found to be 
clinically useful antidepressants with a relatively 
good safety profile. However, recently, reversible 
monoamine A inhibitors have become available in 
the market. 
The popularity of these drugs in psychiatry has 
been up and down. Initially, they were found to be 
useful in the treatment of neurotic depression and in 
phobic anxiety states, while the tricyclics were 
reserved for the treatment of major depression. 
During the 1970's they fell into disrepute because of 
their suspected low efficacy and the danger of hy-
pertension. However, later work (Pare, 1985; Robin-
son, 1978) has shown them to be as effective as 
tricyclic antidepressants. Additionally, they have 
also been found to be useful in the treatment of 
eating and panic disorders and anxiety states 
(Mountjoy et al, 1977; Walsh et al, 1982). 
While the side effects of these drugs and food 
restrictions necessary to take them have been limit-
ing factors for their use thus far, the introduction of 
reversible inhibitors of monoamine oxidase A may 
facilitate their clinical use. The side effects profile 
of these drugs is well delineated (Kurtz & Robinson, 
1988). The most publicized and the most dangerous 
side effect is hypertension while the common ones 
are insomnia, hypotension, sexual side effects, 
weight gain and occasionally mania. 
Abuse of these drugs in not com mon but there are 
thirteen cases of addiction in the literature (Baum-
bacher & Hansen, 1992; Ben-Arie & George, 1979; 
Griffin et & Webb, 1981; Le Gassicke, 1963 & 1965; 
Mielezarek & Johnson, 1963; Shopsin & Kline, 
1976; Swanson et al, 1973; Vartzopoulas & Krull, 
1991; Westermeyer, 1989; Pitt, 1974). Of these, 
seven men and five women were addicted to tranyl-
cypromine, while only one patient (male) was ad-
dicted to phenelzine. Most of these patients had 
neurotic depression and ten of them had an addition-
al diagnosis eittter history of past drug abuse or 
personality disorder (Shopsin & Kline, 1976). It is 
possible that the euphoric effect of tranylcypromine 
may contribute to addiction or abuse. MAOI 
withdrawal symptoms, such as headache, shivering, 
and intense cold, lasting for a week have been 
reported (Tyrer, 1984). 
We encountered three patients who received 
MAOI under psychiatric care. They were all self 
medicated by increasing the doses on their own, 
experienced euphoria, visited various physicians to 
obtain MAOI prescriptions, and manifested toxic 
states. These reports may be of interest to clinicians 
who prescribe MAOI in their clinical practice. 
CASE REPORTS 
Case 1: This fifty four year old Caucasian profes-
sional male was admitted to a hospital on three 
different occasions within a period of three months 
with transient hypertension and euphoria, resolving 
each time after brief hospitalization. His symptoms 
were headache, numbness and tingling, and sensory 
loss in different part of the body. lixtensive work up 
did not reveal any abnormality. During his fourth 
admission, his blood pressure reading was 180/110, 
with mild euphoria and lack of concern about his J.ANANTHETAL 
physical state. A neurological examination and 
laboratory data were within normal limits. Due to 
the difficulty posed by the clinical picture in arriving 
at a diagnosis, psychiatry was consulted. 
During psychiatric examination, he admitted 
seeing a psychiatrist for depression during the pre-
vious four years. As he failed to respond to adequate 
tricyclic therapy, tranylcypromine 20mg daily was 
prescribed. It lifted his mood, anergia and fatigue. 
As the euphoric effect wore off over time, he ob-
tained medications from different physicians and 
gradually increased the dose. At the time of admis-
sion, he had been taking 200 to 400 mg of tranyl-
cypromine daily. The patient had functioned well as 
a professional and had no prior addictions. Mental 
status examination revealed euphoria, mild ir-
ritability, and headache. No hallucinations or 
delusions were observed. Preoccupation or craving 
for the drug were notably absent. On the unit, tranyl-
cypromine 20 mg was prescribed and he was 
watched carefully. He signed out, against medical 
advice, a week later. 
Case 2: A thirty five year old separated 
Caucasian female was admitted to the emergency 
unit of a general hospital experiencing confusion, 
visual hallucinations, irritability, psychomotor ex-
citement and severe hypotension. As an overdose 
was suspected, careful monitoring and supportive 
therapy were instituted. After 48 hours, her blood 
pressure improved and confusion was partially 
lifted. She was admitted to psychiatry with a diag-
nosis of major depression. On examination, she was 
oriented to place and person but not to time, irritable, 
belligerent and confused. She admitted to taking an 
excessive amount of phenelzine to "feel good". She 
did not mind feeling dizzy as long as she felt high. 
The symptoms abated over a period of two weeks. 
She had many past admissions with a diagnosis of 
major depression, substance abuse and personality 
disorder. Phenelzine was withdrawn, but the patient 
continued to crave for this medication. 
Case3: This fifty fourycarold male was severely 
depressed following his recent divorce. He had had 
many episodes of depression along with schizoid 
personality unresponsive to adequate dose of 
tricyclics, with and without thyroid and lithium sup-
plementation. Subsequently, amphetamine had been 
prescribed with reasonable improvement. He abused 
amphetamine for years. As the patient continued to 
have depression, inability to communicate with 
people and irritable outbursts, amphetamine was 
discontinued and tranylcypromine 20 mg daily was 
prescribed with a good clinical response. Over time, 
the patient started increasing the dose on his own by 
obtaining prescriptions from a number of 
psychiatrists. He was subsequently admitted to the 
hospital with tremulousness, tachycardia, shivering, 
perspiration and aches and pains all over the body. 
During the interview, it was revealed that he had 
been taking 100 to 160mgof tranylcypromine daily. 
Two weeks after 20 mg daily of tranylcypromine in 
the hospital, all his depressive symptoms were 
resolved but the patient continued to be socially 
withdrawn. 
DISCUSSION 
Various adverse effects of MAOI's are well es-
tablished, but withdrawal as well as addiction are 
rarely reported. The literature indicates that those 
who were addicted to amphetamine or other drugs 
in the past, are at increased risk to become addicted 
to a MAOI. One of our patients had a normal, 
another a schizoid, and the third, an addictive per-
sonality. While two of our patients were addicted in 
the past to amphetamine, all the three experienced a 
good antidepressant response with euphoria. The 
fact that these patients actively sought medication 
for years in spite of dangerous side effects indicates 
addiction rather than dependence. Also of interest is 
the phenelzine addiction in one of our patients. Such 
an addiction is rarely reported in the literature. 
Hence, it is important not to prescribe MAOI's to 
patients who have a history of amphetamine and 
other addictions. Even though MAOI addiction is a 
rare occurrence, such a precaution is relevant, as the 
use of these medications is on the increase. A careful 
scrutiny is called for when patients on MAOI's ask 
for an increase in dose, develop hypotension or 
hypertension, or manifest toxicity. Otherwise, they 
may go unrecognized as occurred in one of our 
patients. 
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